Successes in antiviral drug discovery: a tribute to Nick Meanwell

Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12:96–102. Bartenschlager R, Ahlborn-Laake R, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993;67:3835–44. Lohmann V, Körner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997;71:8416–28. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005;79:9369–80. Lohmann V, Bartenschlager R. On the history of hepatitis C virus cell culture systems. J Med Chem. 2014;57:1627–42. Meanwell NA, Philip S.Portoghese Medicinal Chemistry Lectureship Curing hepatitis C virus infection with direct-acting antiviral agents. The arc of a medicinal chemistry triumph. J Med Chem. 2016. 2015;62:7311–51. Ingallinella P, Altamura S, Bianchi E, Taliani M, Ingenito R, Cortese R, et al. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry. 1998;37:8906–14. Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3−4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol. 2011;29:993–1003. Njoroge FG, Chen KX, Shih N-Y, Piwinski JJ. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res. 2008;41:50–9. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186–9. Scola PM, Wang AX, Good AC, Sun L-Q, Combrink KD, Campbell JA, et al. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014;57:1708–29. Scola PM, Sun L-Q, Wang AX, Chen J, Sin N, Venables BL, et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014;57:1730–52. Poole RW. Daclatasvir + Asunaprevir: first global approval. Drugs. 2014;74:1559–71. Lok A, Gardiner AS, Lawitz DF, Martowell E, Everson C, Ghalib GT, et al. Preliminary study of two antiviral agents for Hepatitis C genotype 1. N Eng J Med. 2012;366:216–24. Chung RT. A watershed moment in the treatment of hepatitis C. N Eng J Med. 2012;366:273–5. Bhatia HK, Singh H, Grewal N, Natt NK. Sofosbuvir: a novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother. 2014;5:278–84. Taylor DR. Evolution of cell culture systems for HCV. Antivir Ther. 2013;18:523–30. Romine JL, St. Laurent DR, Leet JE, Martin SW, Serrano-Wu MH, Yang F, et al. Inhibitors of HCV NS5A: from iminothiazolidinones to symmetrical stilbenes. ACS Med Chem Lett. 2011;2:224–9. Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, et al. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem. 2014;57:2013–32. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96–100. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA. 2013;110:3991–6. Gentile I, Maraolo AE, Buonomo AR, Zapulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363–77. Zhuang L, Li J, Zhang Y, Ji S, Li Y, Zhao Y, et al. Real world effectiveness of direct-acting antiviral regimens against hepatitis C virus (HCV) genotype 3 infection: a systematic review and meta-analysis. Ann Hepatol. 2021;23:100268. Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F, et al. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double blind clinical trial. J Antimicrob Chemother. 2022;77:758–66. Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double blind, randomized controlled trial. J Antimicrob Chemother. 2021;76:753–7. Zheng X, Hudyma TW, Martin SW, Bergstrom C, Ding M, He F, et al. Synthesis and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus. Bioorg Med Chem Lett 2011;21:2925–9. Gallo RC, Montagnier LM. The discovery of HIV as the cause of AIDS. N Engl J Med. 2003;349:2283–5. Hammer SM. Advances in antiretroviral therapy. AIDS. 1996;10:S1–S11. Lv Z, Chu Y, Wang Y. HIV protease inhibitors, a review of molecular selectivity and toxicity. HIV AIDS. 2015;7:95–104. Wang T, Yin Z, Zhang Z, Bender JA, Yang Z, Johnson G, et al. Inhibitors of human immunodeficiency virus type 1(HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]-pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected. Subj J Med Chem. 2009;52:7778–87. Bartoli G, Dalpozzo R, Nardi M. Applications of Bartoli indole synthesis. Chem Soc Rev. 2014;43:4728–50. Zhang Z, Yang Z, Meanwell NA, Kadow JF, Wang T. A general method for the preparation of 4- and 6-azaindoles. J Org Chem. 2002;67:2345–7. Wang T, Ueda Y, Zhang Z, Yin Z, Matiskella J, Pearce BC, et al. Discovery of the human immunodeficiency virus type 1 (HIV-1) attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir. J Med Chem. 2018;61:6308–27. Nowicka-Sans B, Gong Y-F, McAuliffe B, Dicker I, Ho H-T, Zhou N, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012;56:3498–507.